Previous 10 | Next 10 |
2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – Mechanism may enhance antitumor responses with immunothera...
2024-04-05 16:42:08 ET Gainers: Applied Optoelectronics ( AAOI ) +4% . Outset Medical ( OM ) +2% . SunPower Corporation ( SPWR ) +2% . Applied Therapeutics ( APLT ) +2% . Enovix Corporation ( ENVX ) +2% . Losers: Palladyn...
2024-03-20 20:14:44 ET Summary CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point t...
2024-03-14 18:28:43 ET The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock down by more than 6% Thursday, a much steeper fall than the 0.6...
2024-03-14 11:22:56 ET More on Coherus BioSciences Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Q4 2023 Earnings Preview Biggest stock movers today: Boeing, NuSt...
2024-03-14 08:28:15 ET Losers: Spruce Biosciences ( SPRB ) -78% reports FY results Solidion Technology ( STI ) -30% climbs 10% on $3.85M private placement . Hello Group ( MOMO ) -16% after Q4 earnings release . Pagaya Technologies Ltd ( ...
2024-03-13 20:56:10 ET Coherus BioSciences, Inc. (CHRS) Q4 2023 Results Conference Call March 13, 2024 05:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - Chief Executive Officer Paul Reider - Chief Commercial Officer R...
2024-03-13 16:12:50 ET More on Coherus BioSciences Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Q4 2023 Earnings Preview Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more Read the full articl...
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales of $52.4 milli...
News, Short Squeeze, Breakout and More Instantly...
Coherus BioSciences Inc. Company Name:
CHRS Stock Symbol:
NASDAQ Market:
Coherus BioSciences Inc. Website:
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – ...
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI ...
– New $38.7 million term loan with a May 2029 maturity – – $37.5 million royalty monetization financing based on future sales of LOQTORZI ® and UDENYCA ® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioScience...